Importantly, our findings, along with those of other researchers, revealed that a MAP4K4 inhibitor, GNE‐495, impedes hepatocellular cancer cell migration and invasion, indicating that MAP4K4‐targeting therapies may alleviate HCC progression. This evidence concerns the gene MAP4K4 and hepatocellular carcinoma.